• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子和雌激素通过独立途径协同作用,促进乳腺肿瘤细胞释放血管生成趋化因子 CXCL8。

Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.

机构信息

Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

出版信息

Neoplasia. 2011 Mar;13(3):230-43. doi: 10.1593/neo.101340.

DOI:10.1593/neo.101340
PMID:21390186
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3050866/
Abstract

The tumor microenvironment contains multiple cancer-supporting factors, whose joint activities promote malignancy. Here, we show that epidermal growth factor (EGF) and estrogen upregulate in an additive manner the transcription and the secretion of the angiogenic chemokine CXCL8 (interleukin 8 [IL-8]) in breast tumor cells. In view of published findings on cross-regulatory interactions between EGF receptors and estrogen receptors in breast tumor cells, we asked whether the additive effects of EGF and estrogen were due to their ability to (1) induce intracellular cross talk and amplify shared regulatory pathways or (2) act in independent mechanisms, which complement each other. We found that stimulation by EGF alone induced the release of CXCL8 through signaling pathways involving ErbB2, ErbB1, Erk, and phosphoinositide 3-kinase (PI3K). ErbB2 and Erk were also involved in estrogen activities on CXCL8 but to a lower extent than with EGF. However, in the joint stimulatory setup, the addition of estrogen to EGF has led to partial (ErbB2, ErbB1, Erk) or complete (PI3K) shutoff of the involvement of these activation pathways in CXCL8 up-regulation. Furthermore, when costimulation by EGF + estrogen was applied, the effects of estrogen were channeled to regulation of CXCL8 at the transcription level, acting through the transcription factor estrogen receptor α (ERα). In parallel, in the joint stimulation, EGF acted independently at the transcription level through AP-1, to upregulate CXCL8 expression. The independent activities of EGF and estrogen on CXCL8 transcription reinforce the need to introduce simultaneous targeting of ErbBs and ERα to achieve effective therapy in breast cancer.

摘要

肿瘤微环境包含多种支持癌症的因素,其共同作用促进了恶性肿瘤的发生。在这里,我们表明表皮生长因子(EGF)和雌激素以累加的方式上调乳腺癌细胞中血管生成趋化因子 CXCL8(白细胞介素 8 [IL-8])的转录和分泌。鉴于已发表的关于 EGF 受体和雌激素受体在乳腺癌细胞中交叉调节相互作用的研究结果,我们想知道 EGF 和雌激素的累加作用是否是由于它们能够(1)诱导细胞内串扰并放大共享的调节途径,还是(2)以相互补充的独立机制发挥作用。我们发现,EGF 单独刺激通过涉及 ErbB2、ErbB1、Erk 和磷酸肌醇 3-激酶(PI3K)的信号通路诱导 CXCL8 的释放。ErbB2 和 Erk 也参与了雌激素对 CXCL8 的作用,但程度低于 EGF。然而,在联合刺激设置中,雌激素的加入导致 ErbB2、ErbB1、Erk 部分(ErbB2、ErbB1、Erk)或完全(PI3K)关闭这些激活通路在 CXCL8 上调中的参与。此外,当应用 EGF+雌激素的共刺激时,雌激素的作用被引导到 CXCL8 的转录水平调节,通过转录因子雌激素受体α(ERα)起作用。同时,在联合刺激中,EGF 通过 AP-1 独立地在转录水平上作用,上调 CXCL8 的表达。EGF 和雌激素对 CXCL8 转录的独立作用强化了同时靶向 ErbBs 和 ERα 以实现乳腺癌有效治疗的必要性。

相似文献

1
Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells.表皮生长因子和雌激素通过独立途径协同作用,促进乳腺肿瘤细胞释放血管生成趋化因子 CXCL8。
Neoplasia. 2011 Mar;13(3):230-43. doi: 10.1593/neo.101340.
2
Role of EGF/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells.表皮生长因子/表皮生长因子受体1(EGF/ERBB1)在乳腺癌细胞中催乳素受体转录调控中的作用,该调控独立于雌激素和催乳素。
Oncotarget. 2016 Oct 4;7(40):65602-65613. doi: 10.18632/oncotarget.11579.
3
Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks.表皮生长因子通过多种分子相互作用在雌激素受体α阳性乳腺肿瘤细胞中诱导WISP-2/CCN5表达。
Mol Cancer Res. 2005 Mar;3(3):151-62. doi: 10.1158/1541-7786.MCR-04-0130.
4
Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.雌激素对丝裂原活化蛋白激酶的激活是由雌激素受体α36(ER-α36)在雌激素受体阳性乳腺癌细胞中介导的。
J Steroid Biochem Mol Biol. 2014 Sep;143:434-43. doi: 10.1016/j.jsbmb.2014.06.009. Epub 2014 Jun 25.
5
A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.一种新型的紫杉烷衍生物,HMQ1611,通过雌激素受体 α 和表皮生长因子受体信号通路抑制乳腺癌细胞生长。
Cancer Prev Res (Phila). 2012 Jun;5(6):864-73. doi: 10.1158/1940-6207.CAPR-11-0575. Epub 2012 Apr 11.
6
The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.EGF-EGFR 信号通路在肝癌炎症微环境中的作用。
J Cell Mol Med. 2014 Feb;18(2):218-30. doi: 10.1111/jcmm.12153. Epub 2013 Nov 25.
7
Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway.雌激素相关受体α1的转录活性部分通过ErbB2/HER2信号通路进行调控。
Mol Cancer Res. 2007 Jan;5(1):71-85. doi: 10.1158/1541-7786.MCR-06-0227.
8
Calmodulin modulates Akt activity in human breast cancer cell lines.钙调蛋白调节人乳腺癌细胞系中的Akt活性。
Breast Cancer Res Treat. 2009 Jun;115(3):545-60. doi: 10.1007/s10549-008-0097-z. Epub 2008 Jun 28.
9
Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol.新生期暴露于己烯雌酚的小鼠阴道中erbBs信号通路和雌激素受体α的非雌激素依赖性激活。
Oncogene. 2004 Jan 15;23(2):340-9. doi: 10.1038/sj.onc.1207207.
10
Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells.鞘氨醇 1-磷酸受体 4 通过 HER2(表皮生长因子受体 2)调节 MDA-MB-453 乳腺癌细胞中的细胞外信号调节激酶 1/2。
J Biol Chem. 2010 Nov 12;285(46):35957-66. doi: 10.1074/jbc.M110.117945. Epub 2010 Sep 13.

引用本文的文献

1
A Tumor Microenvironment-Driven Network Regulated by STAT3 and p65 Negatively Controls the Enrichment of Cancer Stem Cells in Human HR+/HER2- Breast Cancer.由STAT3和p65调控的肿瘤微环境驱动网络对人HR+/HER2-乳腺癌中癌症干细胞的富集起负向调控作用。
Cancers (Basel). 2023 Apr 12;15(8):2255. doi: 10.3390/cancers15082255.
2
Single-cell analysis of menstrual endometrial tissues defines phenotypes associated with endometriosis.单细胞分析月经子宫内膜组织定义与子宫内膜异位症相关的表型。
BMC Med. 2022 Sep 15;20(1):315. doi: 10.1186/s12916-022-02500-3.
3
Sex Bias in Differentiated Thyroid Cancer.甲状腺癌的性别偏见。
Int J Mol Sci. 2021 Nov 30;22(23):12992. doi: 10.3390/ijms222312992.
4
Estrogen and EGFR Pathways Regulate Notch Signaling in Opposing Directions for Multi-Ciliogenesis in the Fallopian Tube.雌激素和 EGFR 通路以相反的方向调节输卵管多纤毛发生中的 Notch 信号转导。
Cells. 2019 Aug 19;8(8):933. doi: 10.3390/cells8080933.
5
Interleukin 8 in progression of hormone-dependent early breast cancer.白细胞介素8在激素依赖性早期乳腺癌进展中的作用
J Biosci. 2017 Jun;42(2):265-274. doi: 10.1007/s12038-017-9679-4.
6
Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.微环境网络促进肿瘤异质性,并在腔面A型乳腺肿瘤细胞中富集转移性癌干细胞样细胞。
Oncotarget. 2016 Dec 6;7(49):81123-81143. doi: 10.18632/oncotarget.13213.
7
The role of chemokines in breast cancer pathology and its possible use as therapeutic targets.趋化因子在乳腺癌病理学中的作用及其作为治疗靶点的可能用途。
J Immunol Res. 2014;2014:849720. doi: 10.1155/2014/849720. Epub 2014 Aug 5.
8
Cancer subclonal genetic architecture as a key to personalized medicine.癌症亚克隆遗传结构是个性化医疗的关键。
Neoplasia. 2013 Dec;15(12):1410-20. doi: 10.1593/neo.131972.
9
Progression of luminal breast tumors is promoted by ménage à trois between the inflammatory cytokine TNFα and the hormonal and growth-supporting arms of the tumor microenvironment.腔面型乳腺肿瘤的进展是由炎症细胞因子 TNFα 与肿瘤微环境中激素和生长支持这两个部分之间的“三角关系”所促进的。
Mediators Inflamm. 2013;2013:720536. doi: 10.1155/2013/720536. Epub 2013 Dec 4.
10
Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection.HCV 感染时 NF-κB 和干扰素调节因子 3 对 CXCL10 启动子的直接、干扰素非依赖性激活。
J Virol. 2014 Feb;88(3):1582-90. doi: 10.1128/JVI.02007-13. Epub 2013 Nov 20.

本文引用的文献

1
Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.IL-8 和 CXCR2 基因多态性对乳腺癌易感性和侵袭性的联合作用。
BMC Cancer. 2010 Jun 12;10:283. doi: 10.1186/1471-2407-10-283.
2
Fulvestrant - a novel endocrine therapy for breast cancer.氟维司群——一种新型乳腺癌内分泌治疗药物。
Curr Med Chem. 2010;17(10):902-14. doi: 10.2174/092986710790820633.
3
Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.氟维司群:一种用于雌激素敏感型乳腺癌的独特的抗内分泌药物。
Expert Opin Pharmacother. 2010 Apr;11(5):807-16. doi: 10.1517/14656561003641982.
4
Adjuvant aromatase inhibitor therapy: outcomes and safety.辅助芳香化酶抑制剂治疗:疗效和安全性。
Cancer Treat Rev. 2010 May;36(3):249-61. doi: 10.1016/j.ctrv.2009.12.010. Epub 2010 Feb 4.
5
EGFR signaling and drug discovery.表皮生长因子受体信号通路与药物研发。
Oncology. 2009;77(6):400-10. doi: 10.1159/000279388. Epub 2010 Feb 2.
6
Tumor self-seeding by circulating cancer cells.肿瘤细胞循环中的自我播种。
Cell. 2009 Dec 24;139(7):1315-26. doi: 10.1016/j.cell.2009.11.025.
7
In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo.GPR30/GPER-1,一种膜雌激素受体的体内功能:从发现到体内功能。
Endocr J. 2010;57(2):101-7. doi: 10.1507/endocrj.k09e-332. Epub 2009 Dec 8.
8
The unfolding stories of GPR30, a new membrane-bound estrogen receptor.GPR30,一种新的膜结合雌激素受体的展开故事。
J Endocrinol. 2010 Feb;204(2):105-14. doi: 10.1677/JOE-09-0242. Epub 2009 Sep 18.
9
Membrane oestrogen receptor alpha signalling to cell functions.膜雌激素受体 α 信号转导至细胞功能。
J Physiol. 2009 Nov 1;587(Pt 21):5019-23. doi: 10.1113/jphysiol.2009.177097. Epub 2009 Aug 17.
10
A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.2009年激素受体阳性乳腺癌患者治疗的最新进展。
Clin Breast Cancer. 2009 Jun;9 Suppl 1:S6-S17. doi: 10.3816/CBC.2009.s.001.